The early amplification of its gene in pancreatic cancer described in this study (Figures 1 and 2) and its oncogenic activity reported in the literature prompted us to further study the role of REG4 in pancreatic tumorigenicity and in resistance of pancreatic cancer to gemcitabine treatment. The gene discussed is REG4; the disease is pancreatic neoplasm.